• Topotecan HCl: Mechanistic Insights and DNA Damage Precision

  2026-04-23

  Explore the advanced mechanisms of Topotecan HCl, a leading topoisomerase 1 inhibitor. This in-depth analysis reveals how precise DNA damage induction transforms oncology assays, with new guidance grounded in breakthrough neuroinflammation research.

• Chloroquine (SKU BA1002): Reliable Solutions for Cell Assays

  2026-04-22

  Chloroquine (SKU BA1002) stands out as a validated autophagy inhibitor and anti-inflammatory agent for malaria and rheumatoid arthritis research. This article delivers scenario-driven, evidence-based guidance to biomedical scientists, addressing real laboratory challenges and demonstrating how APExBIO’s Chloroquine ensures reproducibility, workflow efficiency, and robust data quality.

• Anlotinib hydrochloride (SKU C8688): Optimizing Angiogenesis

  2026-04-22

  This article equips biomedical researchers and lab technicians with scenario-driven solutions for angiogenesis and proliferation assays using Anlotinib hydrochloride (SKU C8688). Drawing on validated literature and product data, we demonstrate how this multi-target tyrosine kinase inhibitor delivers reproducibility, sensitivity, and workflow confidence for cell-based experiments.

• Dextromethorphan hydrobromide: Technical Guide for Neuroprot

  2026-04-21

  Dextromethorphan hydrobromide is a high-purity NMDA receptor antagonist intended for research on neuroprotection and excitotoxicity inhibition, particularly in in vitro and in vivo neuroscience workflows. It is not suitable for diagnostic or clinical use, and optimal performance depends on precise adherence to solubility, handling, and storage protocols.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-04-21

  This study demonstrates that pharmacological inhibition or genetic knockdown of BRD4 sensitizes diverse cell lines to erastin-induced ferroptosis by increasing reactive oxygen species and suppressing FSP1 expression. The findings highlight the mechanistic link between BRD4 activity, ferroptosis regulation, and potential anti-cancer strategies leveraging BET inhibitors.

• Foretinib (GSK1363089): Precision Multikinase Inhibition in

  2026-04-20

  Foretinib (GSK1363089) enables nanomolar-precision inhibition of tumor cell growth and metastasis, streamlining both in vitro and in vivo cancer research. This guide delivers practical protocols, troubleshooting insights, and evidence-driven optimization to maximize assay rigor and translational impact.

• Nocodazole: Microtubule Polymerization Inhibitor for Cell Cy

  2026-04-20

  Nocodazole is a potent microtubule polymerization inhibitor widely used in microtubule dynamics research and cell cycle regulation assays. Its reversible disruption of β-tubulin enables precise manipulation of mitosis and apoptosis in cancer research. APExBIO supplies validated Nocodazole (A8487) for robust, reproducible experimental workflows.

• Amorolfine Hydrochloride: Antifungal Reagent for Advanced Ce

  2026-04-19

  Amorolfine Hydrochloride stands out as a high-purity antifungal reagent, enabling researchers to dissect fungal cell membrane disruption and ploidy-dependent stress with precision. Its robust solubility profile and validated mechanism of action empower innovative workflows in antifungal resistance and cell biology research.

• RBMS1 Loss Enhances Checkpoint Immunity in Triple-Negative B

  2026-04-18

  This study identifies RBMS1 as a key regulator of immune suppression in triple-negative breast cancer (TNBC). Loss of RBMS1 reduces PD-L1 glycosylation, destabilizes PD-L1, and enhances anti-tumor T cell immunity, suggesting a new combinatorial strategy to improve immunotherapy outcomes.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Resea

  2026-04-17

  This study presents a streamlined protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with enhanced self-renewal and differentiation capacity. The findings highlight the potential of hiPSC-IOs as a physiologically relevant in vitro model for pharmacokinetic studies, addressing limitations seen in animal models and traditional cell lines.

• DMH1: Precision ALK2 Inhibition for Organoid and NSCLC Resea

  2026-04-16

  DMH1 empowers researchers with highly selective ALK2 inhibition, uniquely enabling precise modulation of BMP signaling in both organoid engineering and non-small cell lung cancer models. Its proven effectiveness in balancing self-renewal and differentiation as well as suppressing lung cancer cell migration makes it indispensable for advanced experimental workflows.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-04-15

  A recent study reveals that naturally occurring angiotensin peptides, including truncated forms such as Angiotensin 1/2 (5-7), can significantly enhance the binding of the SARS-CoV-2 spike protein to its alternative receptor AXL. This finding expands our understanding of peptide-mediated viral entry mechanisms and suggests new considerations for cardiovascular and infectious disease research.

• Rifampin: Applied Workflows for Bacterial Resistance Mechani

  2026-04-14

  Rifampin, a benchmark rifamycin antibiotic, provides precise and selective inhibition of bacterial transcription, empowering advanced studies in resistance mechanisms and synthetic biology. This article details optimized experimental workflows, troubleshooting strategies, and actionable protocol recommendations to maximize reproducibility and efficiency in the laboratory.

• Aminopeptidase Inhibitors in Next-Gen Cancer Therapy: Insigh

  2026-04-13

  This review critically evaluates the mechanistic role and therapeutic positioning of aminopeptidase inhibitors, such as bestatin (Ubenimex), in cancer treatment. It synthesizes recent findings on enzyme function, inhibitor efficacy, and challenges in overcoming multidrug resistance, providing a framework for future translational research.

• Optimizing Cancer Epigenetics with Decitabine (5-Aza-2'-deox

  2026-04-12

  This article provides evidence-based guidance for biomedical researchers and lab technicians seeking to optimize cell-based assays and epigenetic studies using Decitabine (5-Aza-2'-deoxycytidine) (SKU A1906). Drawing on peer-reviewed studies and validated protocols, it addresses real-world experimental challenges, supports protocol design, and demonstrates the reliability of APExBIO's Decitabine for translational research.

457 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page